屋尘螨类变应原治疗变应性鼻炎的疗效与安全性——PROACAROS研究:一项随机对照试验方案
本研究为双盲、安慰剂对照、随机平行的III期临床试验,计划在西班牙16个中心纳入250例儿童和成人常年性变应性鼻炎患者,评估屋尘螨聚合类变应原提取物混合物(Beltavac®)皮下免疫治疗12个月的疗效与安全性,主要结局为鼻炎联合症状与用药评分(CSMS),采用手机应用自评收集。
要点
- 研究评估屋尘螨聚合类变应原混合物皮下免疫治疗常年性变应性鼻炎的疗效与安全性。
- 主要疗效结局为通过手机应用自评收集的鼻炎联合症状与用药评分(CSMS)。
- 试验设计遵循EMA和EAACI关于变应性鼻炎产品临床开发的指南。
核心结论
- 作者工作假设为:研究产品在伴或不伴哮喘的变应性鼻炎患者中,按EAACI定义的标准在提供临床显著改善方面优于安慰剂。
- 本III期临床试验预期为屋尘螨类变应原免疫治疗的疗效与安全性提供科学证据。
研究设计与样本
- 双盲、安慰剂对照、随机平行分组III期临床试验。
- 计划纳入250例来自西班牙16个中心的儿童和成人常年性变应性鼻炎患者。
- 患者按1:1比例随机分配至活性免疫治疗组或安慰剂组。
- 实验组接受12次每月皮下注射免疫治疗,每种变应原效价为2 RC/ml。
主要发现
- 主要疗效结局为鼻炎联合症状与用药评分(CSMS),由患者通过为本研究专门开发的手机应用自评收集。
- 主要次要结局包括扩展的鼻结膜炎症状CSMS、鼻炎控制、特异性IgE和IgG4值、生活质量及不良反应数量。
- 还将评估健康相关的直接和间接成本,并使用多个探索性参数评估哮喘严重程度。
关键数值与推荐
- 入选标准为中度或重度鼻炎症状,伴或不伴哮喘,确诊屋尘螨致敏,且无可能干扰计划评估的相关合并症。
- 研究设计遵循EMA和EAACI关于变应性鼻炎治疗产品临床开发的指南。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an important heterogeneity of the clinical research done to date for allergen immunotherapy (AIT). We plan to assess the safety and efficacy of a house dust mite (HDM) polymerized allergen extract mixture for allergic rhinoconjunctivitis (AR) according to both the EMA and European Academy of Allergy and Clinical Immunology (EAACI) guidelines for the clinical development of products for the treatment of AR. METHODS: We will perform a double-blind, placebo-controlled, randomized parallel group phase III clinical trial to assess the clinical efficacy and safety of a polymerized Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract mixture (Beltavac®) to treat perennial AR in children and adults. Patients with moderate or severe rhinitis symptoms, either associated or not with asthma and confirmed HDM sensitization and without relevant concomitant conditions that may interfere with the planned evaluations test are eligible. Patients will be randomized in a 1:1 ratio to either the active AIT or placebo. The experimental group will receive 12 monthly AIT doses via subcutaneous route with a potency of 2 RC/ml per allergen. The expected sample size is 250 patients from 16 sites in Spain. The main efficacy outcome is the Combined Symptom and Medication Score (CSMS) for rhinitis. It will be patients' self-assessed and collected through a phone App developed ad hoc for the study to improve the patient adherence and the quality of data. Main secondary outcomes include expanded CSMS for rhinoconjunctivitis symptoms, control of rhinitis, specific IgE and IgG4 values, quality of life, and the number of adverse reactions. Health-related direct and indirect costs will be also evaluated. Finally, several exploratory parameters will be used to assess the severity of asthma. DISCUSSION: This phase III clinical trial will be of interest to contribute to the scientific evidence about the efficacy and safety of AIT with allergoids. Our working hypothesis is that the investigational product in patients with AR associated or not with asthma is superior to placebo in providing a clinically significant improvement according to the standards defined by the EAACI. This trial will also supply valuable information about patients reported outcomes using health technology for rhinoconjunctivitis and asthma assessment. TRIAL REGISTRATION: EudraCT 2018-003427-11. Date on which this record was first entered in the: 2021-06-14.
引用
- Buendía-Jiménez I, Matas-Ros M, Garriga-Baraut T, et al. Efficacy and safety of a house dust mites allergoid in patients with allergic rhinitis-PROACAROS study: protocol for a randomized controlled trial. Trials. 2025. PMID: 40437636. doi:10.1186/s13063-025-08875-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。